An antibody for detecting Porphyromonas gingivalis Mfa1 and its application

By developing nano-antibody with strong specificity and high sensitivity and corresponding detection kits, the problems of insufficient specificity and low sensitivity in Porphyromonas gingivalis detection methods were solved, and a fast and efficient detection effect was achieved.

CN118598992BActive Publication Date: 2024-11-05GUANGZHOU MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411060277.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-05
Estimated Expiration
2044-08-05

AI Technical Summary

Technical Problem

The existing Porphyromonas gingivalis detection methods have problems such as insufficient specificity, low sensitivity, complex operation and high cost, making it difficult to quickly and efficiently identify the bacteria.

Method used

A nano-antibody with strong specificity and high sensitivity was developed for detecting Porphyromonas gingivalis Mfa1, and a rapid detection kit based on this antibody can specifically recognize Mfa1 antigen fragments, with high stability and distinction. .

Benefits of technology

It realizes high sensitivity and strong specificity detection of Porphyromonas gingivalis, which can process a large number of samples at the same time, which is fast and simple, without cross-reactivity, and the detection results are accurate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118598992B_ABST
    Figure CN118598992B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biotechnology, and specifically relates to an antibody for detecting Mfa1 of Porphyromonas gingivalis and an application thereof. The antibody is a nano antibody Nb-PG-8 as shown in SEQ ID NO:13. The present invention also discloses a method for preparing the nano antibody and a method for detecting Porphyromonas gingivalis based on the nano antibody Nb-PG-8. The nano antibody can quickly, sensitively and accurately detect Mfa1 of Porphyromonas gingivalis, and can also achieve more sensitive, highly specific and faster detection of Porphyromonas gingivalis, eliminating false positive interference caused by cross-reactions, and showing good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology detection, and specifically relates to an antibody for detecting Porphyromonas gingivalis and an application thereof. Background Art

[0002] Porphyromonas gingivalis is a Gram-negative, obligate anaerobe that is widely considered to be one of the main pathogens of periodontal disease. It interacts with host cells through its surface structural proteins such as pili and fimbriae, thereby promoting its colonization and spread in oral biofilms.

[0003] Mfa1 is a major fimbriae component in Porphyromonas gingivalis. It is part of the fimbriae system and is mainly responsible for the adhesion function of bacteria. Mfa1 fimbriae is composed of multiple proteins, including Mfa1, Mfa2, Mfa3, Mfa4 and Mfa5. These proteins form a complex structure through a specific polymerization mechanism, in which Mfa1 serves as the main structural protein, while Mfa3, Mfa4 and Mfa5 serve as auxiliary proteins to participate in the assembly and functional regulation of fimbriae.

[0004] The main methods for detecting and determining Porphyromonas gingivalis are:

[0005] Microscopic observation: This method is usually used for preliminary identification of microorganisms. It is based on the shape, size and staining reaction of the microorganism. The advantage of this method is that it is simple and fast, but the disadvantage is that it cannot identify the species level and can generally only distinguish between major categories;

[0006] Culture counting method: This method is often used to determine the number of bacteria. The advantage is that the size, shape, and color of the bacterial colonies can be visually seen, but the disadvantage is that specific culture conditions are required and microorganisms that cannot grow on specific culture media cannot be detected.

[0007] Molecular biology methods: such as PCR (polymerase chain reaction), bacterial fingerprint analysis (such as DGGE, TGGE), high-throughput sequencing, etc. The advantages are high accuracy, strong reproducibility, and the ability to identify bacteria to the level of species or even strains. However, the disadvantages are high technical requirements for operation, high cost, and the need for corresponding equipment and software for data analysis. Compared with nanoantibodies, the reaction affinity is greatly reduced. Summary of the invention

[0008] The purpose of the present invention is to overcome the shortcomings of the aforementioned various Porphyromonas gingivalis detection methods and to provide a nano-antibody against Porphyromonas gingivalis Mfa1 with strong specificity and high sensitivity, as well as a rapid and efficient detection method for Porphyromonas gingivalis.

[0009] To achieve the above object, the present invention provides an antibody for detecting Porphyromonas gingivalis Mfa1, characterized in that the antibody is a nanobody;

[0010] Preferably, the amino acid sequence framework region of the Nanobody includes FR1 as shown in SEQ ID NO: 6, FR2 as shown in SEQ ID NO: 7, FR3 as shown in SEQ ID NO: 8 and FR4 as shown in SEQ ID NO: 9, and the complementary variable region includes CDR1 as shown in SEQ ID NO: 10, CDR2 as shown in SEQ ID NO: 11 and CDR3 as shown in SEQ ID NO: 12;

[0011] Preferably, the nanobody is as shown in SEQ ID NO: 13;

[0012] In another preferred embodiment of the present invention, the use of the nanobody in the preparation of a kit for detecting Porphyromonas gingivalis is also provided;

[0013] In another preferred embodiment of the present invention, a kit for detecting Porphyromonas gingivalis is also provided, characterized in that the kit contains a nanobody as shown in SEQ ID NO: 13;

[0014] In another preferred embodiment of the present invention, a host cell is also provided, wherein the host cell expresses the Nanobody shown in SEQ ID NO: 13;

[0015] The technical solution of the present invention has the following effects:

[0016] 1. The present invention prepares a nanobody against Porphyromonas gingivalis Mfa1, which can specifically recognize the antigen fragment of Porphyromonas gingivalis Mfa1, wherein the nanobody is shown in SEQ ID NO: 13;

[0017] 2. The nanoantibody-based Porphyromonas gingivalis antibody detection method or detection kit provided by the present invention has the effects of high sensitivity, good stability, and strong specificity, and can detect a large number of samples at the same time;

[0018] 3. The method provided by the present invention for quickly and easily detecting Porphyromonas gingivalis in a sample is to perform a glass plate agglutination test on the sample to be tested using a reagent comprising a nanobody as shown in SEQ ID NO: 13. The method has a rapid, sensitive, and highly discriminatory detection effect, and has no cross-reactivity with Group A Streptococcus, Neisseria, anaerobic Streptococcus, Lactobacillus, and Staphylococcus epidermidis during the detection process. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 Agarose gel electrophoresis of the first and second rounds of PCR;

[0020] Figure 2 ELISA screening of phages displaying nanobodies;

[0021] Figure 3 SDS-PAGE of nanobody Nb-PG-8;

[0022] Figure 4 Sensitivity identification of nanoantibody Nb-PG-8;

[0023] Figure 5 Correlation analysis of Porphyromonas gingivalis antibody detection based on nanoantibody Nb-PG-8; DETAILED DESCRIPTION

[0024] The methods and applications of the present invention have been described through preferred embodiments. Relevant personnel can obviously modify or appropriately change and combine the methods and applications herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0025] Example 1: Immunization and screening of anti-Pg-Mfa1 nanobodies

[0026] 1.1 Preparation of Pg-Mfa1 antigen fragment: Using the Mfa1 gene of Porphyromonas gingivalis as a template, the Pg-Mfa1 antigen fragment as shown in SEQ ID NO:1 was obtained by PCR reaction, and the recombinant expression plasmid of Pg-Mfa1 was constructed. The expression plasmid was transferred into BL21 (DE3) competent cells and cultured to OD600 of 0.6-0.8. The expression was induced overnight with a final concentration of 1 mmol / L IPTG at 25°C, and Ni-Agarose Resin was purified by column treatment to prepare the Pg-Mfa1 antigen fragment for camel immunization: DFGTYYENPTIDPATHNAILKPKKGIKVNSAVGKTVKVYVVLNDIAGKAKALLANVNAADFDAKFKEIIELSTQAQALGTVADGPNPATAAGKIAKKNGTTDETIMMTCLQPSDALTIEAAVSEANAIAGIKNQAKVTVERSVARAMVSTKAQSYEIKATTQIGEIAAGSVLATITDIRWVVAQGERRQYLSKKRGTVPENTWVTPGSGFVPTSST (SEQ ID NO: 1);

[0027] 1.2 Immunization of Pg-Mfa1 antigen fragment: The Pg-Mfa1 antigen fragment prepared in the previous step was divided into 4 tubes, each tube containing 200 μg. Adult male alpacas in good physical condition were selected and immunized by subcutaneous injection in the scapula. The immunization interval was 2 weeks, and a total of 4 immunizations were performed. The protein amount for each immunization was 200 μg. Complete Freund's adjuvant (Sigma) was used for the first immunization, and incomplete Freund's adjuvant (Sigma) was used for the second to fourth immunizations. After the third immunization, procoagulant blood was collected from the alpaca, and the serum was separated for ELISA to detect the immunization effect.

[0028] 1.3 Amplification of nanoantibodies: Total RNA from alpaca peripheral lymphocytes was extracted and reversed into cDNA. The total RNA obtained was used as a template and oligo(dT)15 was used as a primer for reverse transcription to synthesize the first chain of cDNA to obtain a cDNA library. The synthesized cDNA was used as a template and CALL001 and CALL002 were used as primers to perform the first round of PCR amplification of VHH fragments: The nanoantibody immune library was constructed using the nested PCR method. The primers for the first round of PCR amplification were CALL001-F and CALL002-R, where CALL001-F corresponds to the leader region of the alpaca antibody and CALL002-R corresponds to the second constant region (CH2) of the alpaca antibody. The leader region and CH2 region of conventional antibodies (900 bp) and heavy chain antibodies (700 bp) can be amplified respectively. The specific method is as follows:

[0029] Table 1: First round PCR reaction system

[0030]

[0031] Table 2: Primers for the first round of PCR amplification

[0032]

[0033] Table 3: First round PCR amplification program

[0034]

[0035] After the PCR product was separated by 1% agarose gel electrophoresis, a 700 bp DNA fragment was purified and recovered using a kit, which was the first round of PCR amplification of the VHH gene. The specific electrophoresis identification diagram is shown in Figure 1 A, Lane 1: Marker represents DL1200 marker, Lane 2: VHH gene product amplified by the first round of PCR; Figure 1 A results show that the first round of PCR amplification results are in line with expectations.

[0036] The second round of PCR amplification was performed using the VHH gene product amplified in the first round as a template and VHH-F and VHH-R as primers.

[0037] Table 4: Second round PCR reaction system

[0038]

[0039] Table 5: Second round PCR amplification primers

[0040]

[0041] Table 6: Second round PCR amplification program

[0042]

[0043] After the PCR product was separated by 1% agarose gel electrophoresis, a 400 bp DNA fragment was purified and recovered using a kit, namely the VHH fragment. The specific electrophoresis diagram is shown in Figure 1 B, Lane 1: Marker represents DL 1000 marker, Lane 2: VHH gene product amplified by the second round of PCR, Figure 1 B Result shows that the second round of PCR amplification results are in line with expectations.

[0044] 1.4 Construction of anti-Pg-Mfa1 phage-displayed nanoantibody library: pCANTAB5e plasmid was treated with double enzyme digestion and VHH gene was amplified by the second round of PCR. Then, the VHH fragment purified by double enzyme digestion was ligated with the vector pCANTAB5e using T4 ligase (Thermo).

[0045] Table 7: Ligation reaction system

[0046]

[0047] Take 3 μL of the above ligation product and add it to 50 μL E. coli electroporation competent cells. After mixing, add it to a pre-cooled 0.1 cm electroporation cup (Bio-RAD), and then place it on the Bio-rad electroporation instrument for electroporation. The electroporation conditions are: 2.0 kV, 250 Ω, 15 μF. Immediately after electroporation, add 1 mL of preheated SOC liquid culture medium to the electroporation cup, and transfer it to a clean sterilized 15 mL shaking tube after pipetting. As described above, perform ten electroporations, mix the bacterial solutions after ten electroporations, and slowly shake at 37°C for 1 hour.

[0048] Transfer all the revived bacterial solution into 200 mL BL medium and shake at 37°C 250 rpm. When the OD600 value reaches 0.5, add 1 mL 1×10 12 pfu of phage M13m19, after standing at 37°C for 1 hour, continue shaking for 2 hours, add kanamycin to a final concentration of 70μg / mL, and shake overnight. The next day, the overnight bacteria were centrifuged at 4°C 10000rpm for 15min, the supernatant was transferred to a sterile centrifuge bottle, 1 / 4 volume of 5xPEG / NaCl was added, and after standing on ice for 2 hours, 4°C 12000rpm centrifuged for 20min, and the precipitate was dissolved with 10mL of sterile resuspension solution to obtain the amplified anti-Pg-Mfa1 phage display nanoantibody library.

[0049] 1.5 Identification of the selected phage-displayed nanoantibodies by ELISA: The coated Pg-Mfa1 antigen fragment was serially diluted with coating buffer and coated on a 96-well ELISA plate, 100 μL / well, and placed in a refrigerator at 4 °C overnight. The next day, the ELISA plate was taken out and returned to room temperature, 200 μL PBST solution was injected into each well, shaken on a shaker for 3 min, the washing solution was shaken off vigorously, and patted dry on absorbent paper, and continued to wash twice. The following washing methods are the same. After sufficient washing, the ELISA plate was blocked with blocking buffer, 200 μL / well, incubated in a 37 °C incubator for 2 h, and then taken out and dried for use; 100 μL / well phage M13m19 supernatant was added, incubated at 37 °C for 1 h, washed and patted dry. 100 μL of 1:3000 diluted enzyme-labeled anti-M13 secondary antibody was added to each well and incubated at 37 °C for 1 h. 100 μL of colorimetric solution (TMB to substrate solution ratio of 1:5) was added to each well, and the reaction was carried out at 37 °C in the dark for 15 min. After removal, 100 μL of stop solution (2 mol / L sulfuric acid) was added to each well, and the absorbance value A450 ( Figure 2 ).

[0050] Figure 2 The results showed that the PG-8 phage-displayed nanoantibody with the strongest binding ability to the Pg-Mfa1 antigen fragment was the positive phage.

[0051] Example 2 Identification and expression of anti-Pg-Mfa1 nanobody

[0052] The PG-8 phage expressing the nanobody was sent to a sequencing company for gene sequencing. The sequencing results were analyzed using Bioedit software, and the antibody gene sequence was analyzed by logging on to the IMGT website (www.http: / / www.imgt.org / ) to determine the framework region and complementary determining region of the antibody sequence.

[0053] Table 8: Nanobody sequences

[0054]

[0055] The PG-8 phage plasmid was extracted and transformed into E. coli Top10F cells by heat shock for induced expression. The nanoantibody protein Nb-PG-8 was purified using a Ni-NTA agarose column. SDS-PAGE identification results Figure 3 It showed that lane 1 had only one target protein band of 13 KDa, indicating that Nb-PG-8 was successfully expressed and purified well.

[0056] Example 3 Affinity identification of anti-Pg-Mfa1 nanobody

[0057] Pg-Mfa1-BSA was diluted to 0.5 µg / mL using 0.05 mol / L carbonate buffer (pH 9.6), and 100 µL was coated on each well of the ELISA plate at 4 °C overnight. The plate was washed three times with 0.01% PBST, and 300 µL of 5% skim milk was added to each well, and the plate was blocked at 37 °C for 1 h. The plate was washed three times with 0.01% PBST, and 50 µL of serially diluted Pg-Mfa1 standards (0.01, 0.2, 0.25, 0.5, 1.5, 6, and 10 ng / mL) and an equal amount of enzyme-labeled nanobody antibody Nb-PG-8-HRP (horseradish peroxidase labeled) were added to each well, and the competition reaction was carried out at 37 °C for 1 h. The plate was washed five times with 0.01% PBST, and 100 µL of TMB was added to each well, and the plate was developed at 37 °C in the dark for 7 min. 50 µL of 1 mol / L HCL was immediately added to terminate the reaction. The calculation of binding rate is shown in formula (2), with binding rate (%) as the ordinate and mass concentration of Pg-Mfa1 standard (ng / mL) as the abscissa. Origin pro 9.5 was used to perform logistic four-parameter fitting and draw the competitive inhibition curve. Binding rate / %=B / B0×100, where: B is the absorbance of the well with added Pg-Mfa1 standard; B0 is the absorbance of the well without added Pg-Mfa1 standard.

[0058] Figure 4 The results show the data obtained from kinetic binding and the IC of Nb-PG-8 was calculated. 50 The value is 1.065ng / mL.

[0059] Example 4: Porphyromonas gingivalis antibody detection

[0060] Dilute Porphyromonas gingivalis to 3.34 × 10 2 , 1.17×10 3 ,3.54×10 3 , 2.48×10 4 ,3.46×10 5cfu / mL series of concentrations, and set up a PBST blank control; add 100μL sample to each well to coat the ELISA plate; wash the reaction plate three times with PBST, 3 minutes each time, 200μL / well, and then spin dry the reaction plate; add 10μg / mL horseradish peroxidase-labeled nanoantibody Nb-PG-8-HRP to each well, 100μL / well, and incubate at 4℃ overnight; wash the reaction plate three times with PBST, 3 minutes each time, 200μL / well, and then spin dry the reaction plate; CBS containing 0.2% gelatin, 200μL / well, block at 37℃ for 2h; repeat the above operation to wash clean, and incubate at 37℃ for 1h. Wash the reaction plate three times with PBST, 3 minutes each time, 200μL / well, and then spin dry the reaction plate; then spin dry the reaction plate; add substrate TMB 100 μL / well, color development for 10min; add stop solution 50μL / well, and detect OD450nm with an ELISA reader, see Figure 5 .

[0061] Figure 5 The results showed that the detection range of the Porphyromonas gingivalis antigen detection obtained by the present invention was 1×10 3 cfu / mL, correlation R 2 =0.9975.

[0062] Example 5: Specificity detection results of nanobody Nb-PG-8 on different strains

[0063] The glass plate agglutination test was performed with standard samples of Group A Streptococcus, Porphyromonas gingivalis, Neisseria, anaerobic Streptococcus, Lactobacillus, and Staphylococcus epidermidis and nanoantibody Nb-PG-8, respectively. A small amount of selected colonies of Group A Streptococcus, Porphyromonas gingivalis, Neisseria, anaerobic Streptococcus, Lactobacillus, and Staphylococcus epidermidis on the plate was picked up with an inoculation loop, mixed in normal saline, and then dropped onto a clean glass slide marked in advance, and nanoantibody Nb-PG-8 was added at the same time. Control groups of Group A Streptococcus, Porphyromonas gingivalis, Neisseria, anaerobic Streptococcus, Lactobacillus, Staphylococcus epidermidis and normal saline and nanoantibody Nb-PG-8 and normal salt were set up. The results are shown in Table 9, which show that the nanoantibody Nb-PG-8 has good specificity and is positive only with Porphyromonas gingivalis, and negative with Group A Streptococcus, Neisseria, anaerobic Streptococcus, Lactobacillus, and Staphylococcus epidermidis.

[0064] Table 9 Specificity identification of nanoantibody Nb-PG-8

[0065]

[0066] Note: + indicates a positive result of the glass plate agglutination test; - indicates a negative result of the glass plate agglutination test.

[0067] The results in Table 9 show that the nanoantibody Nb-PG-8 can specifically detect Porphyromonas gingivalis; and has no cross-reactivity with Group A Streptococcus, Neisseria, anaerobic Streptococcus, Lactobacillus, and Staphylococcus epidermidis.

[0068] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the attached claims.

Claims

1. An antibody for detecting Porphyromonas gingivalis Mfa1, characterized in that: The antibody is a nanobody, the amino acid sequence framework region of the nanobody includes FR1 as shown in SEQ ID NO:6, FR2 as shown in SEQ ID NO:7, FR3 as shown in SEQ ID NO:8 and FR4 as shown in SEQ ID NO:9, and the complementary variable region includes CDR1 as shown in SEQ ID NO:10, CDR2 as shown in SEQ ID NO:11 and CDR3 as shown in SEQ ID NO:

12.

2. An antibody for detecting Porphyromonas gingivalis Mfa1, characterized in that: The antibody is a nanobody as shown in SEQ ID NO:

13.

3. Use of the antibody for detecting Porphyromonas gingivalis Mfa1 according to claim 1 or 2 in the preparation of a kit for detecting Porphyromonas gingivalis.

4. A kit for detecting Porphyromonas gingivalis, characterized in that: The kit contains the antibody for detecting Porphyromonas gingivalis Mfa1 according to claim 1 or 2.

5. A recombinant vector, characterized in that: The vector has a nucleotide sequence encoding the antibody for detecting Porphyromonas gingivalis Mfa1 according to claim 1 or 2.

6. A host cell, characterized in that The host cell expresses the antibody for detecting Porphyromonas gingivalis Mfa1 according to claim 1 or 2.

7. A method for producing a nanobody for detecting Porphyromonas gingivalis Mfa1, characterized in that: Cultivate the host cell of claim 6 to obtain a culture solution containing the antibody for detecting Porphyromonas gingivalis Mfa1 of claim 1 or 2, and separate and purify the antibody for detecting Porphyromonas gingivalis Mfa1 from the culture solution.